Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing

Multiple myeloma (MM) is the second most common hematological malignancy. It is characterized by abnormal transformation and uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM), which can destroy bone structure and inhibit hematopoiesis. Although there are new therapeutic methods, they are not curative, mainly because it is difficult to deliver an effective amount of drug to BM, leading to a failure to eradicate MM cells inside the BM. BM homing is an important and unique characteristic of MM cells and it is mainly affected by surface molecules on the tumor cell membrane. Inspired by this mechanism, an MM‐mimicking nanocarrier is developed by coating bortezomib (BTZ)‐loaded poly(ε‐caprolactone)–poly(ethylene glycol)–poly(ε‐caprolactone) (PCEC) nanoparticles with the MM cell membrane. The MM‐mimicking nanoparticles can enter the BM based on BM homing as a “Trojan horse” and target the tumor cells through homologous targeting. In this way, drug availability at the myeloma site is enhanced so as to inhibit MM growth. In addition, these MM‐mimicking nanoparticles can escape phagocytosis by the MPS and have a long circulation effect. The in vivo therapeutic results demonstrate an excellent treatment efficacy for MM. Accordingly, this strategy may be a promising platform for the treatment of MM. The insufficient delivery of drug limits the therapeutic effect of multiple myeloma. A myeloma cell‐mimicking nanocarrier, which can enter bone marrow based on bone marrow homing and target tumor cells through homologous targeting, is developed. Thus, the amount of drug available at the myeloma site in the bone marrow is increased and an enhanced therapeutic effect is achieved.